Form Type:  CT ORDER
Filing Date:  11/8/2018 
CIK:  0000921299 
Address:  409 ILLINOIS STREET 
City, State, Zip:  SAN FRANCISCO, California 94158 
Telephone:  415-978-1200 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.77 (-1.74%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
Trade FGEN now with 

© 2019  
Description of Business
We are a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. We have applied our pioneering expertise in hypoxia-inducible factor ("HIF") and connective tissue growth factor ("CTGF") biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, our most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase ("HIF-PH") activity that has received New Drug Application ("NDA") approval in anemia associated with chronic kidney disease ("CKD") in dialysis-dependent ("DD") patients from the National Medical Products Administration ("NMPA") (previously known as the China Food and Drug Administration) of the People's Republic of China ("China"). In conjunction with our collaboration partners, AstraZeneca AB ("AstraZeneca") and Astellas Pharma Inc.
Register and access this filing in: